These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18048114)

  • 1. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
    Igaz P; Rácz K; Tulassay Z
    Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
    Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
    Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up of patients with ECL cell-derived tumours.
    Sagatun L; Fossmark R; Jianu CS; Qvigstad G; Nordrum IS; Mjønes P; Waldum HL
    Scand J Gastroenterol; 2016 Nov; 51(11):1398-405. PubMed ID: 27309188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailored intermittent therapy of carcinoid.
    Kinová S; Duris I; Kratochvíl'ová E; Kovácová E; Koren M
    Hepatogastroenterology; 2007 Sep; 54(78):1716-9. PubMed ID: 18019702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract]   [Full Text] [Related]  

  • 7. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
    Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
    Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
    Skinazi F; Zins M; Menu Y; Bernades P; Ruszniewski P
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):673-8. PubMed ID: 8853257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Carcinoid tumors].
    Pregun I; Bodoky G; Rácz K; Tulassay Z
    Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
    Modlin IM; Pavel M; Kidd M; Gustafsson BI
    Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
    Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
    Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New diagnostic method in pulmonary carcinoid].
    Csiszér E; Antus B; Himber G; Hertel K; Fillinger J
    Magy Onkol; 2007; 51(3):225-8. PubMed ID: 17922062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy.
    Bondanelli M; Ambrosio MR; Zatelli MC; Cavazzini L; Al Jandali Rifa'y L; degli Uberti EC
    World J Gastroenterol; 2005 Apr; 11(13):2041-4. PubMed ID: 15801004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
    Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
    Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoid of the pancreas.
    Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
    Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoid tumour.
    McStay MK; Caplin ME
    Minerva Med; 2002 Oct; 93(5):389-401. PubMed ID: 12410171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
    Molenaar JP; Baten A; Blokx WA; Hoogendam A
    Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreoscan in patients with bronchial carcinoid tumours.
    Granberg D; Sundin A; Janson ET; Oberg K; Skogseid B; Westlin JE
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):793-9. PubMed ID: 14974924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Somatostatin analogues in the treatment of carcinoid].
    Bednaríková M; Valík D; Vyzula R
    Cas Lek Cesk; 2008; 147(4):233-5. PubMed ID: 18578378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.